Patients' preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine

Journal of Headache and Pain

Volumn 6, Issue 3, 2005, Pages 112-120

  Dowson, Andrew J ^a   Tepper, Stewart J ^b   Dahlöf, Carl ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c Gothenburg Migraine Clinic   (Sweden)

Author keywords

Acute treatment; Migraine; Patient preference; Patient satisfaction; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; BUCLIZINE; CAFFEINE; CODEINE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DICHLORALPHENAZONE; DIHYDROERGOTAMINE; DOMPERIDONE; ELETRIPTAN; ERGOTAMINE; IBUPROFEN; ISOMETHEPTENE; METOCLOPRAMIDE; NARATRIPTAN; NARCOTIC AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TOLFENAMIC ACID; ZOLMITRIPTAN;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; META ANALYSIS; MIGRAINE; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; ANALGESICS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOTAMINE; HEALTH CARE SURVEYS; HUMANS; MIGRAINE DISORDERS; PATIENT SATISFACTION; TRYPTAMINES;

EID: 21444451816     PISSN: 11292369     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10194-005-0164-3     Document Type: Review

References (52)

1. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287
2. Fox AW (2000). Comparative tolerability of oral 5-HT1B/1D agonists. Headache 40:521-527
3. Gawel MJ, Worthington I, Maggisano A (2001) A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 28:30-41
4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358:1668-1675
5. Salonen R (2000) Drug comparisons: Why are they so difficult? Cephalalgia 20[Suppl 2]:25-32
6. Pilgrim AJ (1991) Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 31:295-299
7. Cady RK, Sheftell F, Lipton RB et al (2000) Early treatment with sumatriptan enhances pain-free response: Retrospective analysis from three clinical trials. Clin Ther 22:1035-1048
8. Fuseau E, Petricoul O, Sabin A et al (2001) Effect of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during a migraine. Clin Ther 23:242-251
9. Sheftell FD, Fox AW, Weeks RE, Tepper SJ (2001) Differentiating the efficacy of 5HT 1B/D agonists. Headache 41:257-263
10. Goadsby PJ (1999) The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci 26[Suppl 3]:20-26
11. Dahlöf C (2001). Assessing patient preference in migraine treatment. Cephalalgia 21:791-795
12. Loder E, Brandes JL, Silberstein S et al (2001) Preference comparison of rizatriptan ODT 10 mg and sumatriptan 50 mg tablet in migraine. Headache 41:745-753
13. Tfelt-Hansen P, Block G, Dahlöf C et al (2000) International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia 20:765-786
14. Rothwell K, Dowson AJ (1995) Patients' evaluation of acute migraine treatments. Poster presentation at the 6th International Headache Research Seminar, Copenhagen, Denmark
15. Boureau F, Chazot G, Emile J et al (1995) Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group. Eur Neurol 35:264-269
16. Kwong WJ, Chalal R, Putman G et al (2001) Migraine patients prefer Imitrex tablets 50 mg to their usual non-triptan prescription or over-the-counter therapy. Cephalalgia 21:411 (Abstract)
17. Chalal R, Kwong WJ, Putnam G et al (2001) Patient satisfaction with Imitrex tablets 50 mg compared with their usual non-triptan prescription or over-the-counter therapy. Cephalalgia 21:411 (Abstract)
18. Rederich GJ, Newkirk TA, Killilea L, Roberts LD (2001) Migraineurs' preference for sumatriptan over non-triptan therapy in a managed care population. Cephalalgia 21:412 (Abstract)
19. Powers C, Szeto S, Pangtay D et al (2000) Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. Arch Fam Med 9:753-758
20. Sturzenegger M, Daems K, Billeter M (2000) Zolmitriptan in treatment of migraine attack: The ARES study. Schweiz Med Wochenschr 130:1984-1993 (in German)
21. Solomon S, Frishberg B, Hu XH et al (2001) Migraine treatment outcomes with rizatriptan in triptan-naïve patients: A naturalistic study. Clin Ther 23:886-890
22. Robbins L (2001) Triptans vs analgesics: Patient preference. Cephalalgia 21:406 (Abstract)
23. Pascual J, Munoz R, Leira R (2001) An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. Cephalalgia 21:680-684
24. Tfelt-Hansen P, Teall J, Rodriguez F et al (1998) Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 38:748-755
25. Tfelt-Hansen P, Goldstein J, Malbecq W et al (1999) Comparison of rizatriptan and sumatriptan. Headache 39:340-341 (Letter)
26. Bohidar N, Loder E, Guerra F et al (2001) Relationship between patient preference for either rizatriptan orally disintegrating tablet (ODT) 10 mg or sumatriptan tablet 50 mg and speed of pain relief. Cephalalgia 21:422 (Abstract)
27. Pascual J, Bussone G, Hernandez JF et al (2001) Comparison of preference for rizatriptan 10 mg wafer versus sumatriptan 50 mg tablet in migraine. Eur Neurol 45:275-283
28. Goadsby PJ, Ferrari MD, Olesen J et al (2000) Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 54:156-163
29. Colman SS, Brod MI, Krishnamurthy A et al (2001) Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 23:127-145
30. Gerth WC, McCarroll KA, Santanello NC et al (2001) Patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons. Int J Clin Pract 55:552-556
31. Dahlöf C, Jones M, Davis K et al (2004) A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg) and zolmitriptan (2.5 mg) in the acute treatment of migraine. J Headache Pain 5:115-122
32. Dahlöf C (1999) How to assess patient preference of migraine treatments. Cephalalgia 19[Suppl 24]:2-5
33. Sandor P, Agosti R (2001) Which triptan would you like? A retrospective triptan preference study. Cephalalgia 21:408 (Abstract)
34. Sheftell FD, Feleppa M, Tepper SJ et al (2004) Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 44:661-668
35. Dahlöf C (2003) Clinical applications of new therapeutic deliveries in migraine. Neurology 61[8 Suppl 4]:S31-S34
36. Gruffydd-Jones K, Hood CA, Price DB (1997) A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine. Cephalalgia 17:31-36
37. Carpay HA, Matthijsse P, Steinbuch M, Mulder PG (1997) Oral and subcutaneous sumatriptan in the acute treatment of migraine: An open randomized cross-over study. Cephalalgia 17:591-595
38. Dahlöf CG, Saiers J (1998) Sumatriptan injection and tablets in clinical practice: Results of a survey of 707 migraineurs. Headache 38:756-763
39. Dahlöf CGH (2001) Sumatriptan: Pharmacological basis and clinical results. Curr Med Res Opin 17[Suppl 1]:s35-s45
40. Adelman JU, Mannix LK, Von Seggern RL (2000) Rizatriptan tablet versus wafer: Patient preference. Headache 40:371-372
41. Salonen R, Ashford EA, Gibbs M, Hassani H (1999) Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: A double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. Int J Clin Pract Suppl 105:16-24
42. Pfaffenrath V, Cunin G, Sjonell G et al (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 38:184-190
43. Myllylä VV, Havanka H, Herrala L et al (1998) Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 38:201-207
44. Dowson A, Ball K, Haworth D (2000) Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: A randomised UK primary care study. Curr Med Res Opin 16:190-197
45. Oral sumatriptan and Aspirin-plus-Metoclopramide Comparative Study Group (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 32:177-184
46. Tfelt-Hansen P, Henry P, Mulder LJ et al (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346:923-926
47. Freitag FG, Cady R, DiSerio F et al (2001) Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 41:391-398
48. Goldstein J, Silberstein SD, Elkind AH et al (2003) A placebo-controlled comparison of the combination of acetaminophen, aspirin, and caffeine with sumatriptan succinate in the early treatment of migraine: Results from the Asset trial. Neurology 60[Suppl 1]:A171
49. Multinational Oral Sumatriptan and Cafergot Comparative Study Group (1991) A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 31:314-322
50. Gruffydd-Jones K, Kies B, Middleton A et al (2001) Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: A randomized, doubleblind, international study. Eur J Neurol 8:237-245
51. Adelman JU, Lipton RB, Ferrari MD et al (2001) Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 57:1377-1383
52. Silberstein SD, for the US Headache Consortium (2000) Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754-762